Overview

Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

Status:
Active, not recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

Phase 1b: To determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adult subjects with relapsed or refractory (r/r) DLBCL

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Bispecific
Blinatumomab
Pembrolizumab